Zhang Xiaoshen, Zhang Han, Ma Yuxia, Che Wenliang, Hamblin Michael R
Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 200072, China.
Tongji University Cancer Institute, Tongji University School of Medicine, Shanghai, 200092, China.
Cardiol Ther. 2017 Jun;6(1):13-32. doi: 10.1007/s40119-017-0087-5. Epub 2017 Mar 3.
Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
高血压是许多心血管疾病最重要且持续存在的危险因素之一。近年来,全球高血压患病率急剧上升。生活方式和遗传因素通常被认为是高血压发病的主要原因。鉴于高血压的高发病率,为高血压患者制定更新的标准变得不可或缺。根据广泛接受的高血压标准治疗方法,应考虑以下四个基本原则:低剂量;药物应提供长期控制;联合治疗正变得普遍;个性化治疗是一种较新的方法。在大多数高血压患者中,联合治疗可实现血压的充分控制。因此,现在推荐使用作用机制互补的抗高血压药物。在本综述中,我们重点关注奥美沙坦酯单独或与其他抗高血压药物联合使用时的药理学、降压疗效和不良事件(AE)。总之,奥美沙坦酯是一种血管紧张素II受体阻滞剂,在降低和稳定血压方面具有出色疗效。当与钙通道阻滞剂(CCB)和利尿剂联合使用时,奥美沙坦酯对控制患者血压和减少不良事件具有更好的效果。